Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.64 |
| ▸ | MMP13 | P45452 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 3/20 | 0.48 |
| ▸ | MMP14 | P50281 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30613684 | 1.00 | MMP2 (0.64) | MMP2MMP13ALDH1A1TSHRCYP3A4 | |
| SCHEMBL21751532 | 1.00 | MMP2 (0.64) | MMP2MMP13ALDH1A1TSHRCYP3A4 | |
| SCHEMBL21751533 | 1.00 | MMP2 (0.64) | MMP2MMP13ALDH1A1TSHRCYP3A4 | |
| SCHEMBL8065845 | 0.97 | ALDH1A1 (0.62) | MMP2MMP13ALDH1A1TSHRCYP3A4 | |
| SCHEMBL3970619 | 0.85 | ALDH1A1 (0.72) | ALDH1A1TSHRCYP3A4LMNAPSEN1 | |
| SCHEMBL13505088 | 0.84 | MMP2 (0.64) | MMP2MMP13ALDH1A1MMP9MMP14 | |
| SCHEMBL3414517 | 0.84 | MMP2 (0.64) | MMP2MMP13ALDH1A1MMP9MMP14 | |
| SCHEMBL31310951 | 0.84 | MMP2 (0.76) | MMP2MMP13ALDH1A1MMP9MMP14 | |
| SCHEMBL31310960 | 0.84 | MMP2 (0.76) | MMP2MMP13ALDH1A1MMP9MMP14 | |
| SCHEMBL26536260 | 0.84 | MMP2 (0.76) | MMP2MMP13ALDH1A1MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6025177-A | ENANTIOSELECTIVE SYNTHESIS OF CHIRAL ALPHA-HYDROXYCARBOXYLATE BY REACTING A PROCHIRAL ALPHA-KETOCARBOXYLIC ACID WITH A SINGLE ENANTIOMER OF AN N-SUBSTITUTED VICINAL AMINOALCOHOL OF SPECIFIC CYCLOHYDROCARBONS TO FORM ALPHA-HYDROXYCARBOXYLATE | SEPRACOR INC. (US) | 2000-02-15 | — | — | US | claimed |
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240180924-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2024-06-06 | — | — | US | disclosed |
| US-11903950-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | NEWAVE PHARMACEUTICAL INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4110298-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-11-24 | — | — | US | disclosed |
| US-20210332065-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021066873-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020041405-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020041406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-6025177-A | ENANTIOSELECTIVE SYNTHESIS OF CHIRAL ALPHA-HYDROXYCARBOXYLATE BY REACTING A PROCHIRAL ALPHA-KETOCARBOXYLIC ACID WITH A SINGLE ENANTIOMER OF AN N-SUBSTITUTED VICINAL AMINOALCOHOL OF SPECIFIC CYCLOHYDROCARBONS TO FORM ALPHA-HYDROXYCARBOXYLATE | SEPRACOR INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-6013830-A | CHEMICAL INTERMEDIATES FOR OXYBUTYNIN, OXYPHENCYCLIMINE, OXYPHENONIUM BROMIDE, OXYPYRRONIUM BROMIDE, AND OXYSONIUM IODIDE, FOR WHICH CYCLOHEXYLPHENYLGLYCOLIC ACID (CHPGA) IS OF SPECIAL INTEREST; STEREOSELECTIVITY | SEPRACOR INC. (US) | 2000-01-11 | — | — | US | disclosed |
| WO-1999050205-A2 | ASYMMETRIC GRIGNARD SYNTHESIS WITH CYCLIC 1,2 AMINOALCOHOLS | SEPRACOR INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | BCL2, BCL2L1, BCL2L2 | MMP2 765/4885MMP13 2157/4885ALDH1A1 4647/4885 |
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | MMP2 2610/4885MMP13 2494/4885ALDH1A1 3743/4885 |
| US-11903950-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | MMP2 2610/4885MMP13 2494/4885ALDH1A1 3743/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | MMP2 2610/4885MMP13 2494/4885ALDH1A1 3743/4885 |
| US-20240180924-A1 | BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | MMP2 3481/4885MMP13 3562/4885ALDH1A1 3687/4885 |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | MMP2 3425/4885MMP13 2858/4885ALDH1A1 3666/4885 |
| US-20210332065-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | MMP2 2610/4885MMP13 2494/4885ALDH1A1 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.